<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00153660</url>
  </required_header>
  <id_info>
    <org_study_id>8N Study</org_study_id>
    <nct_id>NCT00153660</nct_id>
  </id_info>
  <brief_title>Celecoxib Versus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients</brief_title>
  <official_title>A Double-blind Randomized Comparison of Celecoxib Plus Esomeprazole Versus Naproxen Plus Esomeprazole for Prevention of Recurrent Ulcer Bleeding in Patients With Arthritis and Cardiothrombotic Diseases (NSAID#8 Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare celecoxib plus a PPI (esomeprazole) versus naproxen plus
      a PPI (esomeprazole) in preventing recurrent ulcer bleeding in arthritis patients with a
      history of ulcer bleeding who require concomitant ASA. We hypothesized that among patients
      with a history of ulcer bleeding who require concomitant ASA, celecoxib plus esomprazole
      would be superior to naproxen plus esomeprazole for the prevention of recurrent ulcer
      bleeding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most commonly consumed drugs worldwide
      for the relief of pain and arthritis. However, the use of NSAIDs increases the risk of ulcer
      bleeding by 4-fold. Current evidence indicates that combination of conventional NSAIDs and a
      proton pump inhibitor (PPI) reduces the risk of ulcer complications. The alternative strategy
      is to replace conventional, non-selective NSAIDs with NSAIDs selective for cyclooxygenase-2
      (COX-2 inhibitors). Recently, there are concerns about the cardiovascular safety of COX-2
      inhibitors and conventional NSAIDs. Because of such concern, patients requiring
      anti-inflammatory analgesics who have cardiovascular risk factors (e.g. smoking,
      hypertension, hyperlipidemia, diabetes) should receive prophylactic low-dose aspirin.
      However, concomitant low-dose aspirin negates the gastric sparing effect of COX-2 inhibitors
      and augments the gastric toxicity of nonselective NSAIDs. Thus, gastroprotective agents such
      as PPIs should be co-prescribed to patients with high ulcer risk who are taking aspirin plus
      a COX-2 inhibitor or a nonselective NSAID.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent ulcer bleeding within 18 months according to pre-specified criteria</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>patients' global assessment of arthritis</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major CV events according to the Antithrombotic Trialists' criteria</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-fatal myocardial infarction</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-fatal stroke</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death from a vascular cause</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">514</enrollment>
  <condition>Arthritis</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Cerebrovascular Disorders</condition>
  <arm_group>
    <arm_group_label>NSAID #1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Celecoxib and Naproxen Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSAID #2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naproxen and Celecoxib Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib(drug)</intervention_name>
    <description>Celecoxib 100 mg bd</description>
    <arm_group_label>NSAID #1</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen(drug)</intervention_name>
    <description>Naproxen 500 mg bd</description>
    <arm_group_label>NSAID #2</arm_group_label>
    <other_name>Naprosyn</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age &gt;18,

          2. a history of endoscopically proven gastroduodenal ulcer bleeding,

          3. H. pylori negative

          4. a history of cardiothrombotic disease requiring ASA, and

          5. anticipated regular use of NSAIDs for the duration of trial

        Exclusion Criteria:

          1. concomitant use of anticoagulants;

          2. a history of gastric or duodenal surgery other than a patch repair;

          3. the presence of erosive esophagitis,

          4. gastric outlet obstruction,

          5. renal failure (defined by a serum creatinine level of more than 200 umol/L),

          6. pregnancy,

          7. terminal illness, or

          8. cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis K Chan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Endoscopy Center, Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <state>Hong Kong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>December 30, 2016</last_update_submitted>
  <last_update_submitted_qc>December 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Francis KL Chan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Cerebrovascular Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

